GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Total Receivables

Oculis Holding AG (FRA:CR5) Total Receivables : €1.37 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Total Receivables?

Oculis Holding AG's Total Receivables for the quarter that ended in Mar. 2024 was €1.37 Mil.


Oculis Holding AG Total Receivables Historical Data

The historical data trend for Oculis Holding AG's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Total Receivables Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Receivables
1.05 0.88 1.09 1.28

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.80 2.28 1.28 1.37

Oculis Holding AG Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Oculis Holding AG Total Receivables Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines